UGT2B4 rs1080755: Pharmacogenomics and Drug Metabolism
The rs1080755 variant is a single nucleotide polymorphism located within the UGT2B4 gene. It is currently being studied for its potential role in the metabolic pathways of various medications, including SGLT2 inhibitors, which may influence how these drugs are processed in the body.
What each genotype means
Typical metabolic processing
This genotype represents the most common genetic sequence observed at this position in the UGT2B4 gene. Research into how this specific variant influences the metabolism of SGLT2 inhibitors is currently limited, and there is no consensus on whether this genotype significantly alters drug response. Please discuss your medication regimen and any concerns about drug efficacy or side effects with your healthcare provider.
This is the most frequently observed genotype across most global populations.
Variable metabolic potential
Carrying one copy of the T allele means your genetic profile differs slightly from the most common sequence at this location. While this variant is being studied for its potential role in the metabolic pathway of SGLT2 inhibitors, current evidence is insufficient to determine if this genotype leads to clinically meaningful differences in drug concentration. Always consult your pharmacist or physician before making changes to your prescribed treatment plan.
This heterozygous genotype is found at varying frequencies depending on ancestral background, though specific global prevalence data for this SNP remains sparse.
Potential metabolic variation
This genotype indicates you carry two copies of the T allele at this position. While this variant is investigated in the context of UGT2B4-mediated drug metabolism, the clinical significance of this specific genotype remains uncertain and requires further research to confirm any impact on SGLT2 inhibitor processing. You should continue to follow your clinician's guidance regarding your medication and report any unexpected responses to your treatment.
This genotype is generally less common than the CC or CT genotypes in most studied populations.
Understanding the rs1080755 Variant
The rs1080755 variant is a specific genetic change, or single nucleotide polymorphism (SNP), found within the UGT2B4 gene. In genetics, a SNP represents a variation at a single position in a DNA sequence among individuals. The UGT2B4 gene provides instructions for making an enzyme that belongs to the UDP-glucuronosyltransferase family. These enzymes are primarily responsible for glucuronidation, a process that helps the body transform various substances—including drugs, toxins, and endogenous compounds—into water-soluble forms that can be more easily excreted by the kidneys or liver. Because this variant sits within a gene involved in drug metabolism, researchers investigate whether it alters the efficiency or speed at which these enzymes function, potentially leading to differences in how individuals process specific therapeutic agents.
The Role of UGT2B4 in Metabolism
The UGT2B4 enzyme is a critical component of the Phase II detoxification pathway. By attaching a glucuronic acid molecule to a target substance, the enzyme renders the compound inactive and ready for elimination. This process is essential for maintaining homeostasis and preventing the accumulation of potentially harmful substances. In the context of pharmacogenomics, the activity of UGT enzymes is highly relevant because they metabolize a wide range of clinical drugs. If a genetic variant like rs1080755 affects the expression or catalytic activity of UGT2B4, it could theoretically change the concentration of a drug in the bloodstream. This is particularly important for medications with a narrow therapeutic index, where maintaining a specific concentration is necessary for both safety and efficacy.
Research and Evidence Strength
The association between rs1080755 and drug response is currently categorized as having moderate evidence. While pharmacogenomic research has identified that genetic variations in metabolic genes can influence drug efficacy, the specific clinical impact of rs1080755 remains an area of active investigation. Current studies in the field of pharmacogenomics often look for correlations between specific genotypes and clinical outcomes, such as blood glucose control or drug clearance rates. However, it is important to note that drug response is a complex trait influenced by many factors, including other genetic variants, diet, age, kidney function, and concurrent medications. Consequently, while the link between UGT2B4 and metabolic pathways is biologically plausible, the clinical significance of this specific SNP is still being refined through ongoing research and large-scale genomic studies.
Interpreting Your Genetic Information
If you have received information about your rs1080755 genotype, it is essential to understand that this data is for educational purposes and does not constitute a medical diagnosis. Genetic variants are only one piece of a much larger puzzle regarding how your body responds to medication. You should never use this information to start, stop, or change the dosage of any prescribed medication without consulting your healthcare provider. Pharmacogenomic testing is a tool that clinicians use alongside other clinical markers to personalize treatment plans. If you are concerned about how a medication like an SGLT2 inhibitor is affecting you, discuss your concerns and any genetic information you have with your doctor or pharmacist. They are the best resources to help you interpret these findings in the context of your overall health and treatment goals.
How common is this variant?
The population frequency for rs1080755 is not currently specified in major public databases, and its distribution may vary significantly across different ancestral groups.
Frequently asked questions
What is the UGT2B4 gene?
The UGT2B4 gene encodes an enzyme involved in the glucuronidation process, which helps the body metabolize and eliminate drugs and other compounds.
Can this SNP predict how I respond to SGLT2 inhibitors?
While research suggests a potential link between metabolic genes and drug response, this SNP is not a definitive predictor. Drug response is influenced by many factors, and you should consult your doctor regarding your specific treatment.
Should I change my medication based on this genetic result?
No. You should never change your medication or dosage based on genetic test results without speaking to your healthcare provider, as this could be dangerous.
Where can I find more information about pharmacogenomics?
You can explore resources like PharmGKB or MedlinePlus Genetics for reliable, evidence-based information on how genes affect drug response.
Sources & further reading
Educational information only, last refreshed 9/29/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1080755?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29